Loading clinical trials...
Loading clinical trials...
Angiogenic Switch as Predictor of Response to Chemotherapy in Patients With Metastatic Colorectal Cancer
Conditions
Interventions
Xelox or Xeliri Bevacizumab
Locations
1
Spain
Centro Integral oncológico Clara Campal
Madrid, Spain
Start Date
July 1, 2011
Primary Completion Date
May 1, 2015
Completion Date
May 1, 2015
Last Updated
March 17, 2015
NCT04704661
NCT06696768
NCT05489211
NCT06625775
NCT04657068
NCT06607458
Lead Sponsor
Grupo Hospital de Madrid
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions